Phase 2 HER2-positive Breast Cancer Clinical Trials
31 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 31 trials
Recruiting
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+6 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 2
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Breast CancerHER2-positive Breast Cancer
Jazz Pharmaceuticals125 enrolled21 locationsNCT07102381
Recruiting
Phase 2
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Breast CancerER Positive Breast CancerHER2-positive Breast Cancer+1 more
Ruth O'Regan30 enrolled4 locationsNCT04886531
Recruiting
Phase 2
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
Breast CancerHER2-positive Breast CancerBreast Cancer Stage IV
Memorial Sloan Kettering Cancer Center60 enrolled7 locationsNCT07459673
Recruiting
Phase 2
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
HER2-positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute53 enrolled1 locationNCT05325632
Recruiting
Phase 2
A Study of Surgery and Radiotherapy in People With Breast Cancer
Metastatic Breast CancerHER2-positive Breast Cancer
Memorial Sloan Kettering Cancer Center162 enrolled7 locationsNCT07053085
Recruiting
Phase 2
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Breast CancerHER2-positive Breast Cancer
Dana-Farber Cancer Institute500 enrolled52 locationsNCT04893109
Recruiting
Phase 2
Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study
HER2-positive Breast CancerLMD
Sunnybrook Health Sciences Centre30 enrolled2 locationsNCT06016387
Recruiting
Phase 2
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
Breast CancerHER2-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
University of Chicago74 enrolled4 locationsNCT06348134
Recruiting
Phase 1Phase 2
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
HER2-positive Breast CancerLeptomeningeal DiseaseLeptomeningeal Metastasis
H. Lee Moffitt Cancer Center and Research Institute39 enrolled2 locationsNCT04588545
Recruiting
Phase 2
Basket Study for Oligo-metastatic Breast Cancer
HER2-positive Breast Cancer
The Netherlands Cancer Institute72 enrolled1 locationNCT05982678
Recruiting
Phase 2
Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients
HER2-positive Breast Cancer
Ain Shams University56 enrolled1 locationNCT07233499
Recruiting
Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Breast CancerHER2-positive Breast CancerInvasive Carcinoma of the Breast+2 more
Dana-Farber Cancer Institute375 enrolled32 locationsNCT04569747
Recruiting
Phase 2Phase 3
A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.120 enrolled30 locationsNCT06891833
Recruiting
Phase 2
TRUDI: TDXD+Durva in HER2+/Low IBC
Breast CancerInvasive Breast CancerHER2-positive Breast Cancer+2 more
Filipa Lynce, MD63 enrolled3 locationsNCT05795101
Recruiting
Phase 2
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.120 enrolled1 locationNCT06445400
Recruiting
Phase 2
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
HER2-positive Breast Cancer
MedSIR165 enrolled36 locationsNCT06172127
Recruiting
Phase 2
BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
Breast CancerHER2-positive Breast Cancer
University of Illinois at Chicago28 enrolled1 locationNCT06441890
Recruiting
Phase 2
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
Breast CancerBreast Cancer MetastaticBreast Cancer Female+3 more
Dana-Farber Cancer Institute72 enrolled1 locationNCT06439693
Recruiting
Phase 2
Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer
HER2-positive Breast Cancer
Institut Curie66 enrolled13 locationsNCT05955170